Skye Bioscience Inc (SKYE) Stock Price, Quote & News

Company Profile

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 410 0266

Website: skyebioscience.com

Address:

11250 El Camino Real, Suite 100, San Diego, United States

MissionaryTrader Jun. 3 at 12:40 PM

$SKYE https://www.cnbc.com/2026/06/03/eli-lilly-to-use-glp-1-windfall-to-fund-ma-and-diversify-pipeline.html

1 · Reply

TheMoneyDude777 Jun. 3 at 12:21 PM

$SKYE easy close under .68

0 · Reply

TheMoneyDude777 Jun. 3 at 8:21 AM

$SKYE Woot .7 today! that was fast RS coming for sure! cheer for dirty management!

0 · Reply

Fellforit Jun. 2 at 7:32 PM

$SKYE follow the missionary man-buy, buy, buy...

0 · Reply

TheMoneyDude777 Jun. 2 at 7:26 PM

$SKYE keep up the great work! please

0 · Reply

TheMoneyDude777 Jun. 2 at 7:25 PM

$SKYE wow Amazing!!! I’m so unskilled and that shows how clearly doomed this stock truly is. .6 incoming!!! Amazing $$$

0 · Reply

MissionaryTrader Jun. 2 at 6:14 PM

$SKYE added

0 · Reply

YazzJr Jun. 2 at 5:34 PM

$SKYE That 52 week low is on the table. Like I said before, nothing there to prop this stock up, not unless they pull a rabbit out of their hat ASAP.

0 · Reply

TheMoneyDude777 Jun. 2 at 12:18 PM

$SKYE .7 incoming!

0 · Reply

TheMoneyDude777 Jun. 2 at 1:10 AM

$SKYE lol they keeping hiding my posts scared of the facts

0 · Reply

Skye Bioscience Transcript: AGM 2026

May 20, 2026, 7:00 AM EDT - 15 days ago

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

May 12, 2026, 1:33 PM EDT - 23 days ago

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

2026-05-12T11:22:30.000Z - 23 days ago

Skye Bioscience price target lowered to $6 from $13 at Piper Sandler

2026-05-11T21:09:20.000Z - 24 days ago

Skye Bioscience reports Q1 EPS (32c), consensus (32c)

May 11, 2026, 4:01 PM EDT - 24 days ago

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 11, 2026, 4:00 PM EDT - 24 days ago

Skye Bioscience Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 24 days ago

Skye Bioscience Earnings release: Q1 2026

May 11, 2026, 7:00 AM EDT - 24 days ago

Skye Bioscience Slides: Corporate presentation

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Skye Bioscience Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Skye Bioscience Proxy statement: Proxy filing

Apr 7, 2026, 7:00 AM EDT - 2 months ago

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Skye Bioscience Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Skye Bioscience Proxy statement: Proxy filing

Apr 3, 2026, 7:00 AM EDT - 2 months ago

Skye Bioscience Slides: Corporate presentation

Apr 2, 2026, 7:00 AM EDT - 2 months ago

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Mar 10, 2026, 4:30 PM EDT - 3 months ago

Skye Bioscience Earnings Call Transcript: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 3 months ago

Skye Bioscience Earnings release: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 3 months ago

Skye Bioscience Annual report: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 3 months ago

Skye Bioscience Slides: Q4 2025

2026-03-10T20:12:08.000Z - 3 months ago

Skye Bioscience reports Q4 EPS (36c), consensus (31c)

Mar 10, 2026, 4:01 PM EDT - 3 months ago

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 5, 2026, 7:00 AM EST - 3 months ago

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Feb 21, 2026, 6:00 AM EST - 3 months ago

Skye Bioscience Slides: Corporate presentation

2026-02-02T12:26:39.000Z - 4 months ago

Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab

Feb 2, 2026, 7:00 AM EST - 4 months ago

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

2026-01-29T12:20:16.000Z - 4 months ago

Skye Bioscience presents poster on efficacy of Nimacimab

Jan 29, 2026, 7:00 AM EST - 4 months ago

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

Jan 21, 2026, 7:00 AM EST - 4 months ago

Skye Bioscience to Present Poster at Keystone Obesity Conference

2026-01-12T12:12:34.000Z - 5 months ago

Skye Bioscience provides 2026 corporate outlook

Jan 12, 2026, 7:00 AM EST - 5 months ago

Skye Provides 2026 Corporate Outlook

2026-01-05T12:25:09.000Z - 5 months ago

Skye Bioscience, Halozyme enter collaboration, license agreement

HALO

2026-01-05T12:11:01.000Z - 5 months ago

Halozyme, Skye Bioscience announce global collaboration, license agreement

HALO

Jan 5, 2026, 7:00 AM EST - 5 months ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

HALO

Dec 19, 2025, 2:56 PM EST - 5 months ago

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

Dec 8, 2025, 7:11 AM EST - 6 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Dec 4, 2025, 11:30 AM EST - 6 months ago

Skye Bioscience Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 12:55 PM EST - 6 months ago

Skye Bioscience Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 24, 2025, 7:00 AM EST - 6 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Nov 10, 2025, 4:30 PM EST - 7 months ago

Skye Bioscience Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 7 months ago

Skye Bioscience Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 7 months ago

Skye Bioscience Quarterly report: Q3 2025

2025-11-10T21:16:34.000Z - 7 months ago

Skye Bioscience reports Q3 EPS (32c), consensus (32c)

Nov 10, 2025, 4:01 PM EST - 7 months ago

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

2025-11-05T12:52:20.000Z - 7 months ago

Skye Bioscience to present topline data from CBeyond on nimacimab

Nov 5, 2025, 7:05 AM EST - 7 months ago

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Nov 5, 2025, 7:00 AM EST - 7 months ago

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Oct 28, 2025, 8:00 AM EDT - 7 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

CNTX

2025-10-06T16:15:27.000Z - 8 months ago

Skye Bioscience downgraded to Hold from Buy at Craig-Hallum

2025-10-06T14:35:58.000Z - 8 months ago

Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald

2025-10-06T14:20:06.000Z - 8 months ago

Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald

2025-10-06T12:19:20.000Z - 8 months ago

Why Is Skye Bioscience Stock Down 60% Today?

Oct 6, 2025, 8:00 AM EDT - 8 months ago

Skye Bioscience Transcript: Study Update

Oct 6, 2025, 8:00 AM EDT - 8 months ago

Skye Bioscience Press release: Study Update

Oct 6, 2025, 8:00 AM EDT - 8 months ago

Skye Bioscience Slides: Study Update

2025-10-06T11:16:16.000Z - 8 months ago

Skye Bioscience says nimacimab did not meet primary endpoint in CBeyond study

Oct 6, 2025, 7:09 AM EDT - 8 months ago

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Oct 6, 2025, 7:00 AM EDT - 8 months ago

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Sep 19, 2025, 7:00 AM EDT - 9 months ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 10, 2025, 7:00 AM EDT - 9 months ago

Skye Bioscience Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 7:00 AM EDT - 9 months ago

Skye Bioscience Slides: Corporate Presentation

Sep 4, 2025, 8:00 AM EDT - 9 months ago

Skye Bioscience Transcript: KOL Event

Sep 4, 2025, 7:00 AM EDT - 9 months ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 2, 2025, 7:00 AM EDT - 9 months ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Aug 27, 2025, 7:00 AM EDT - 10 months ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 21, 2025, 7:00 AM EDT - 10 months ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Skye Bioscience Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Skye Bioscience Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Skye Bioscience Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Skye Bioscience Slides: Q2 2025

Aug 7, 2025, 4:01 PM EDT - 10 months ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Jul 30, 2025, 7:00 AM EDT - 11 months ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

MissionaryTrader Jun. 3 at 12:40 PM

$SKYE https://www.cnbc.com/2026/06/03/eli-lilly-to-use-glp-1-windfall-to-fund-ma-and-diversify-pipeline.html

1 · Reply

TheMoneyDude777 Jun. 3 at 12:21 PM

$SKYE easy close under .68

0 · Reply

TheMoneyDude777 Jun. 3 at 8:21 AM

$SKYE Woot .7 today! that was fast RS coming for sure! cheer for dirty management!

0 · Reply

Fellforit Jun. 2 at 7:32 PM

$SKYE follow the missionary man-buy, buy, buy...

0 · Reply

TheMoneyDude777 Jun. 2 at 7:26 PM

$SKYE keep up the great work! please

0 · Reply

TheMoneyDude777 Jun. 2 at 7:25 PM

$SKYE wow Amazing!!! I’m so unskilled and that shows how clearly doomed this stock truly is. .6 incoming!!! Amazing $$$

0 · Reply

MissionaryTrader Jun. 2 at 6:14 PM

$SKYE added

0 · Reply

YazzJr Jun. 2 at 5:34 PM

$SKYE That 52 week low is on the table. Like I said before, nothing there to prop this stock up, not unless they pull a rabbit out of their hat ASAP.

0 · Reply

TheMoneyDude777 Jun. 2 at 12:18 PM

$SKYE .7 incoming!

0 · Reply

TheMoneyDude777 Jun. 2 at 1:10 AM

$SKYE lol they keeping hiding my posts scared of the facts

0 · Reply

TheMoneyDude777 Jun. 2 at 1:09 AM

$SKYE lol .7 incoming!

0 · Reply

TheMoneyDude777 Jun. 1 at 11:45 AM

$SKYE .7 incoming this week summer dilution. getting ready for the RS or closing altogether. prove me wrong! lol

1 · Reply

Fellforit May. 29 at 5:21 PM

$SKYE

0 · Reply

YazzJr May. 29 at 2:57 PM

$SKYE Not a lot to prop this stock up and we have a long way to go before results.

1 · Reply

SuperGreenToday May. 28 at 12:10 AM

$SKYE Share Price: $0.83 Contract Selected: Dec 18, 2026 $2.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.08 – $0.09 Potential Upside: 71% ROI Time to Expiration: 204 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

TheMoneyDude777 May. 26 at 10:15 PM

$SKYE lol

0 · Reply

TheMoneyDude777 May. 26 at 7:26 PM

$SKYE Come back to .7

0 · Reply

MissionaryTrader May. 26 at 3:44 PM

$SKYE annual stock holder meeting, today at 12 EST.

2 · Reply

TheMoneyDude777 May. 26 at 1:56 PM

$SKYE time to come back down!